{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:45:14Z","timestamp":1777927514850,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>BICSTaR is a multi-national, observational cohort evaluating the effectiveness, safety, and patient-reported outcomes (PROs) in treatment-na\u00efve (TN) and -experienced (TE) people with HIV-1 receiving bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in routine clinical care. We present the 12-month (M12) outcomes of the Italian BICSTaR cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants initiating B\/F\/TAF in routine care were prospectively followed. Outcomes included virological and immunologic effectiveness, drug-related adverse events (DRAEs), treatment persistence, and PROs using the HIV Symptom Index (HIV-SI) and the HIV Treatment Satisfaction Questionnaires (HIVTSQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 201 were included (29\u00a0TN, 172\u00a0TE), 83% male, median age 38 years in TN, 48 years in TE. At baseline, 94% of TE had an HIV-1 RNA &lt;50 cp\/mL, 92% switched to B\/F\/TAF for simplification. Overall, 69% reported comorbidities (TN: 59%, TE: 70%). At M12, 88% (23\/26) of TN and 96% (152\/159) of TE had an HIV-1 RNA &lt;50 cp\/mL in the discontinuation = failure analysis (without emergence of resistance to B\/F\/TAF). Median CD4 count changes were +296 cells\/\u00b5L (interquartile range [IQR], 118, 383) in TN, and +23 cells\/\u00b5l (\u2212137, 114) in TE. DRAEs were reported for 5% and led to discontinuation in 1%. M12 persistence on B\/F\/TAF was 97%. TN had a median HIV-SI bothersome symptom count decrease of \u22121.5 (IQR, \u22125.0, 0.0). Median treatment satisfaction change score was +29.0 (21, 30) in TE indicating an improvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world Italian cohort of mostly treatment-experienced people switching for simplification, B\/F\/TAF demonstrated high effectiveness and persistence over 12 months and confirmed the favourable safety profile shown in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>European cohort: EUPAS22185.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624241308372","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:10:03Z","timestamp":1736334603000},"page":"309-318","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness, safety, and patient-reported outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort"],"prefix":"10.1177","volume":"36","author":[{"given":"Andrea","family":"Antinori","sequence":"first","affiliation":[{"name":"National Institute of Infectious Diseases, L. Spallanzani"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"University of Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[{"name":"Cotugno Hospital-A.O. dei Colli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"ASST Ovest Milanese - University of Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[{"name":"ASST Spedali Civili"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Candelaresi","sequence":"additional","affiliation":[{"name":"Marche Polytechnic University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[{"name":"University of Bari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[{"name":"University Hospital \u201cTor Vergata\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Cassidy","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thorpe","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Albini","sequence":"additional","affiliation":[{"name":"Gilead Sciences Srl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Caldera","sequence":"additional","affiliation":[{"name":"Gilead Sciences Srl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Forcina","sequence":"additional","affiliation":[{"name":"Gilead Sciences Srl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[{"name":"University of Turin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"EACS guidelines 12.0 Available at: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001967"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003128"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2043"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab115"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010076"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac018"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593"},{"key":"e_1_3_5_19_2","unstructured":"MedDRA Available at: https:\/\/www.meddra.org."},{"key":"e_1_3_5_20_2","unstructured":"Anatomical therapeutic chemical (ATC) classification Available at: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00449-8"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013050904635"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00121.x"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-019-00203-7"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3351"},{"key":"e_1_3_5_27_2","unstructured":"biktarvy_pi.pdf Available at: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf (accessed 18 January 2023)."},{"key":"e_1_3_5_28_2","unstructured":"Body weight changes during pandemic-related shelter-in-place in a longitudinal cohort study | lifestyle behaviors | JAMA network open | JAMA Network Available at: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777737 (accessed 17 January 2023)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0322-8"},{"key":"e_1_3_5_30_2","unstructured":"Italy Available at: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/italy (accessed 3 April 2023)."},{"key":"e_1_3_5_31_2","unstructured":"Unaids 2021. UNAIDS Available at: https:\/\/www.unaids.org\/en\/resources\/infographics\/girls-and-women-living-with-HIV (accessed 4 January 2024)."}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624241308372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624241308372","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624241308372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:19Z","timestamp":1777675579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624241308372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/09564624241308372"],"URL":"https:\/\/doi.org\/10.1177\/09564624241308372","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}